OSEBX1,423.56+0.84%
EQNR284.60+4.20%
DNB198.35-1.15%
MOWI172.80+0.45%
Brent$71.24-0.32%
EUR/USD1.0824-0.14%
DXY104.18+0.08%
INDICATIVE · SAMPLE DATA
NURE56

Nureca Ltd

Medical Equipment, Supplies & DistributionVerified

Nureca's capital structure is characterized by a low debt-to-equity ratio of 0.03, indicating a conservative leverage approach. The company's liquidity is assessed as medium, with a current ratio of 15.32, suggesting strong short-term liquidity. However, the company has no cash and equivalents and a negative net cash position after subtracting total debt, which could pose liquidity challenges. Profitability metrics show a return on equity of 0.44% and a return on assets of 0.4%, both below the industry median for medical equipment and supplies. The company reported a net income of INR 8.46 million despite an operating loss of INR 98.78 million, indicating non-operating income or gains may be contributing to profitability. Nureca's revenue is concentrated in a few product categories, including respiratory wellbeing, physiotherapy, and cardiac health monitoring. The company's product portfolio spans from chronic disease monitoring devices to lifestyle wellness products, with no disclosed geographic revenue breakdown. This lack of geographic diversification could expose the company to regional economic or regulatory risks. The company's growth trajectory is uncertain, with no specific revenue growth projections provided. Historical financials show a revenue of INR 1.097 billion, but the operating cash flow is negative at INR 190.83 million, and free cash flow is only INR 8.69 million. These figures suggest the company is not generating sufficient cash from operations to sustain growth without external financing. Risk factors include medium liquidity risk due to the absence of cash and equivalents and a negative net cash position. The dilution risk is assessed as low, with no significant dilution sources identified. However, the company's operating loss and negative operating cash flow may necessitate future financing, which could lead to dilution. Recent events and filings do not provide specific details on new product launches or strategic initiatives. The company's financial performance and cash flow position suggest a need for operational improvements or additional capital to support growth.

30-day price · NURE+45.58 (+20.0%)
Low$208.05High$300.00Close$273.00As of17 May, 00:00 UTC
Profile
CompanyNureca Ltd
TickerNURE.NS
SectorHealthcare
BusinessHealthcare Services & Equipment
Industry groupHealthcare Services & Equipment
IndustryMedical Equipment, Supplies & Distribution
AI analysis

Business. Nureca Limited provides home healthcare and wellness products, including non-invasive digital diagnosis and prevention tools for lifestyle diseases, and operates under the Dr. Trust, trumom, and Dr. Physio brands.

Classification. Nureca is classified under the Healthcare sector, specifically in the Medical Equipment, Supplies & Distribution industry, with a confidence level of 0.92.

Nureca's capital structure is characterized by a low debt-to-equity ratio of 0.03, indicating a conservative leverage approach. The company's liquidity is assessed as medium, with a current ratio of 15.32, suggesting strong short-term liquidity. However, the company has no cash and equivalents and a negative net cash position after subtracting total debt, which could pose liquidity challenges. Profitability metrics show a return on equity of 0.44% and a return on assets of 0.4%, both below the industry median for medical equipment and supplies. The company reported a net income of INR 8.46 million despite an operating loss of INR 98.78 million, indicating non-operating income or gains may be contributing to profitability. Nureca's revenue is concentrated in a few product categories, including respiratory wellbeing, physiotherapy, and cardiac health monitoring. The company's product portfolio spans from chronic disease monitoring devices to lifestyle wellness products, with no disclosed geographic revenue breakdown. This lack of geographic diversification could expose the company to regional economic or regulatory risks. The company's growth trajectory is uncertain, with no specific revenue growth projections provided. Historical financials show a revenue of INR 1.097 billion, but the operating cash flow is negative at INR 190.83 million, and free cash flow is only INR 8.69 million. These figures suggest the company is not generating sufficient cash from operations to sustain growth without external financing. Risk factors include medium liquidity risk due to the absence of cash and equivalents and a negative net cash position. The dilution risk is assessed as low, with no significant dilution sources identified. However, the company's operating loss and negative operating cash flow may necessitate future financing, which could lead to dilution. Recent events and filings do not provide specific details on new product launches or strategic initiatives. The company's financial performance and cash flow position suggest a need for operational improvements or additional capital to support growth.
Key takeaways
  • Nureca has a low debt-to-equity ratio, indicating a conservative capital structure.
  • The company's profitability metrics are below industry medians, suggesting operational inefficiencies.
  • Revenue concentration in a few product categories and lack of geographic diversification pose concentration risks.
  • The company's liquidity position is medium, with no cash and equivalents and a negative net cash position.
  • Growth is constrained by negative operating cash flow and low free cash flow.
  • --
  • ## RATIONALES
  • ```json
Financial snapshot
PeriodHA-latest
CurrencyINR
Revenue$1.10B
Gross profit$414.7M
Operating income-$98.8M
Net income$8.5M
R&D
SG&A
D&A
SBC
Operating cash flow-$190.8M
CapEx-$23.1M
Free cash flow$8.7M
Total assets$2.10B
Total liabilities$156.9M
Total equity$1.94B
Cash & equivalents$0.00
Long-term debt$49.7M
Annual history (last 5)
PeriodRevenueOp IncomeNet IncomeFCF
FY0
FY-1
FY-2
FY-3
FY-4
PeriodGross %Op %Net %FCF %
FY0
FY-1
FY-2
FY-3
FY-4
PeriodAssetsEquityCashDebt
FY0
FY-1
FY-2
FY-3
FY-4
PeriodOCFCapExFCFSBC
FY0
FY-1
FY-2
FY-3
FY-4
Quarterly history (last 4)
PeriodRevenueOp IncomeNet IncomeFCF
FQ0
FQ-1
FQ-2
FQ-3
FQ-4
FQ-5
FQ-6
FQ-7
PeriodGross %Op %Net %FCF %
FQ0
FQ-1
FQ-2
FQ-3
FQ-4
FQ-5
FQ-6
FQ-7
PeriodAssetsEquityCashDebt
FQ0
FQ-1
FQ-2
FQ-3
FQ-4
FQ-5
FQ-6
FQ-7
PeriodOCFCapExFCFSBC
FQ0
FQ-1
FQ-2
FQ-3
FQ-4
FQ-5
FQ-6
FQ-7
Valuation
Market price
Market cap
Enterprise value
P/E
Reported non-GAAP P/E
EV/Revenue
EV/Op income
EV/OCF
P/B
P/Tangible book
Tangible book$1.94B
Net cash-$49.7M
Current ratio15.3
Debt/Equity0.0
ROA0.4%
ROE0.4%
Cash conversion-22.6%
CapEx/Revenue-2.1%
SBC/Revenue
Asset intensity
Dilution ratio0.0%
Risk assessment
Dilution riskLow
Liquidity riskMedium
  • Net cash is negative after subtracting total debt.
Industry benchmarks
Activity: Healthcare Services & Equipment · cohort 5 companies
MetricNUREActivity
Op margin-9.0%13.3% medp25 5.9% · p75 13.5%bottom quartile
Net margin0.8%8.6% medp25 2.7% · p75 12.7%bottom quartile
Gross margin37.8%64.0% medp25 60.1% · p75 65.6%bottom quartile
R&D / revenue6.9% medp25 6.7% · p75 7.1%
CapEx / revenue-2.1%3.0% medp25 2.7% · p75 4.5%bottom quartile
Debt / equity3.0%69.3% medp25 63.4% · p75 74.5%bottom quartile
Source data
Underlying data the analysis-pipeline pulls and audits. Fetch timestamps + content hashes show when each source was last refreshed.
Company fundamentalsperiod FQ-7 · history via verified-market-data
no public URL
2026-05-07 22:16 UTC#80562e89
Source: analysis-pipeline (hybrid)Generated: 2026-05-03 18:28 UTCJob: 11e1bb21